![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication July 26, 2004.
Revised September 7, 2004.
Accepted for publication September 9, 2004.
Statins have been reported to lower the risk of developing Alzheimer's disease. However, the mechanism of this potentially important neuroprotective action is not understood. Lowering cholesterol levels does not appear to be the primary mechanism. Statins have pleiotropic effects in addition to lowering cholesterol and statins may act on several different pathways involving distinct gene expression patterns that would be difficult to determine by focusing on a few genes or their products in a single study. In addition, gene expression patterns may be specific to a particular statin. To understand the molecular targets of statins in brain, DNA microarrays were used to identify gene expression patterns in the cerebral cortex of mice chronically treated with lovastatin, pravastatin, and simvastatin. Furthermore, brain statin levels were determined using liquid chromatography-tandem mass spectrometry. These studies revealed 15 genes involved in cell growth, signaling and trafficking that were similarly changed by all three statins. Overall, simvastatin had the greatest influence on expression as demonstrated by its ability to modify the expression of 23 genes, in addition to those changed by all three drugs. Of particular interest, was expression of genes associated with apoptotic pathways that were altered by simvastatin. RT-PCR experiments confirmed the microarray findings. All three drugs were detected in the cerebral cortex and acute experiments revealed that statins are relatively rapidly removed from brain. These results provide new insight into possible mechanisms for the potential efficacy of statins in reducing the risk of Alzheimer's disease and lay the foundation for future studies.
Key words:
Alzheimer's disease, Bcl-2, apoptosis, brain gene expression, cholesterol, statins
This article has been cited by other articles:
|
|
 |
|
  S. M. Ostrowski, B. L. Wilkinson, T. E. Golde, and G. Landreth Statins Reduce Amyloid-beta Production through Inhibition of Protein Isoprenylation J. Biol. Chem., September 14, 2007; 282(37): 26832 - 26844. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Shankaran, C. King, J. Lee, R. Busch, M. Wolff, and M. K. Hellerstein Discovery of Novel Hippocampal Neurogenic Agents by Using an in Vivo Stable Isotope Labeling Technique J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1172 - 1181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Thelen, K. M. Rentsch, U. Gutteck, M. Heverin, M. Olin, U. Andersson, A. von Eckardstein, I. Bjorkhem, and D. Lutjohann Brain Cholesterol Synthesis in Mice Is Affected by High Dose of Simvastatin but Not of Pravastatin J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1146 - 1152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Paintlia, M. K. Paintlia, M. Khan, T. Vollmer, A. K. Singh, and I. Singh HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis FASEB J, September 1, 2005; 19(11): 1407 - 1421. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
